Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers

Trial Profile

Phase II Trial of the Immune Checkpoint Inhibitor Nivolumab in Patients With Select Rare CNS Cancers

Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jul 2017

At a glance

  • Drugs Nivolumab (Primary)
  • Indications CNS cancer; Ependymoma; Germ cell and embryonal neoplasms; Glioma; Gliosarcoma; Medulloblastoma; Meningioma; Papilloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 30 Jun 2017 Status changed from not yet recruiting to recruiting.
    • 28 Jun 2017 Planned initiation date changed from 3 Jul 2017 to 4 Jul 2017.
    • 27 Jun 2017 Planned initiation date changed from 30 Jun 2017 to 3 Jul 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top